Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 147 for “"Mutant p53"”.
-
Targeting mutant p53 in cSCCs
… patients with multiple cSCCs.<br/><br/>Wild-type p53 (wt-p53) has been shown to prevent cSCC development and induce tanning and sunburn responses in skin cells. However, TP53 mutations are found in over half of all human cancers and cSCC is no exception as TP53 mutational frequency in cSCCs is …
-
An investigation of mutant p53 function.
The TP53 tumour suppressor gene is mutated in approximately 50% of all human cancers. The majority of these mutations are missense mutations resulting in the expression of a mutated form of the full-length p53 protein. This mutant protein exhibits a loss of tumour suppressive activity, …
-
ACTIVATING MUTANT P53: A DIRECTED EVOLUTION APPROACH
The tumor suppressor p53 plays a cardinal role in genomic stability and cancer prevention, and hence, realizing new cancer therapeutics lie in dissecting the multitude of complex, yet intricate, cellular networks involving p53. Because inactivating mutations in p53 are a direct cause of 50% of all …
-
Mutant P53 Mechanisms And Functions In Esophageal Cancer
… The most frequently mutated gene in ESCC is TP53. P53R175H (homologous to Trp53R172H in mice) is a common “hot spot” mutation. How p53R175H regulates invasion and metastasis in ESCC remains to be investigated. To address this fundamental question in ESCC and possibly applicable to other …
-
MUTANT P53 AS A THERAPEUTIC TARGET IN CANCER
Identifying therapeutic approaches to target TP53 mutations has the potential to revolutionize cancer treatment. TP53, the gene that encodes the prominent tumor suppressor protein p53, is mutated and inactivated in half of sporadic human tumors. Additionally, individuals who harbor germline TP53 …
-
Regulation of wild-type and mutant p53 activity
The tumour suppressor p53 is extensively regulated by posttranslational modification, including modification by the small Ubiquitin-related modifier SUMO. The data presented here show that MDM2, previously described to promote Ubiquitin, Nedd8 and SUMO-1 modification of p53, can also enhance …
-
Revealing Novel Regulators of Wildtype and Mutant p53 Stability
Tumour suppressor p53 (TP53) is the most frequently mutated gene in cancer. Several hotspot p53 mutants not only lose tumour suppressive capabilities, but also function in a dominant-negative manner, suppressing canonical wild-type p53 functions. Furthermore, some hotspot p53 mutants promote …
-
Investigation of Gain-of-Function Induced by Mutant p53
p53 is mutated in 50% of all human cancers, and up to 70% of lung cancer. Mutant p53 is usually expressed at elevated levels in cancer cells and has been correlated with a poor prognosis. Cancer cells that express mutant p53 show an increase in oncogenic phenotypes including an increase in growth …
-
Characterization and functional analysis of mutant p53 secretome in human cancer
… alterations in human cancer, mutations in the TP53 tumour suppressor gene represent the most common, occurring in approximately 50% of all human cancers. The majority of these mutations in p53 are missense mutations, resulting in cancer cells expressing stable, full-length mutated p53 proteins. …
-
The Role of Mutant P53 in the Pathogenesis of Myelodysplastic Syndromes
… Somatic mutations in the tumor suppressor gene TP53 are found in 10-15% of MDS patients and are associated with poor prognosis and reduced survival. TP53 mutations promote clonal expansion and drive MDS pathogenesis during aging. However, extrinsic factors contributing to the progression of p53 …
-
Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis
p53, a tumour suppressor gene, is considered the guardian of genome which governs several important biological functions including cell cycle arrest, DNA repair and apoptosis. Under normal conditions, p53 is tightly regulated and constitutively expressed at a low level. In human cancers, p53 is one …
-
Regulation of Bax Activation and Apoptosis by Src and Acetylated Mutant p53
… on the expression of the tumor suppressor p53. Acetylation of p53 at carboxy-terminal lysine residues enhances its transcriptional activity associated with cell cycle arrest and apoptosis. Here, we demonstrate that p53 acetylation at K320/K373/K382 is also required for its …
-
Targeting mutant p53 in spontaneous cancer by T cell receptor gene therapy
… against an H-2Kk-presented peptide derived from mutant Trp53. The p53D253E mutation (mp53) was tested as target for neoantigen-specific TCR gene therapy. M2/3-engineered T cells were adoptively transferred into immunodeficient C3HxRag2-/- mice bearing established Ag104A tumors. The transferred T …
-
Reprogramming the Mutant p53 Radiation Response to Delay Secondary Malignancies in Li-Fraumeni Syndrome
… is driven by germline mutations in the TP53 gene which has a broad spectrum of functions including the regulation of the radiation response. Given that aberrant p53 function contributes to radiation vulnerability, there is caution with the use of radiotherapy to treat primary LFS tumors, …
-
MUTANT P53 REGULATION OF CXC-CHEMOKINE EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
… sites of the body. It has been found that both mutant p53 and epidermal growth factor receptor (EGFR) signaling pathways function to increase the expression of CXCL5, which has been identified as a key mediator in the process of tumor metastasis. Previous data from our lab suggested that the p53 …
-
Mutant P53 in pre-leukemic hematopoietic stem cells and the pathogenesis of Myelodysplastic Syndrome
… acquired somatic gain-of-function (GOF) TP53 mutations were identified in the blood of aged healthy individuals as well as in patients with MDS. However, the role of GOF TP53 mutations in clonal hematopoiesis and the pathogenesis of MDS is largely unknown. Based upon our previous studies …
-
An investigation into the role of microvesicles in mutant p53 invasive gain-of-function
p53 is a transcription factor with tumour suppressive attributes which is known to be mutated in over half of human cancers. As well as compromising the ability of p53 to function as a transcription factor, mutations in p53 often result in a gain-of-function phenotype which is characterised by …
-
Influence of genotoxic drug-induced post-translational modifications on mutant p53 stability and oncogenic activities
The tumour suppressor p53 is often disrupted by missense mutations that can result in p53 protein accumulation and acquisition of novel oncogenic activities. Various studies have demonstrated that DNA-damaging drugs currently used in the clinic aimed at activating wild type p53, can also stabilise …
-
Study of the Gain-of-Function Mutant p53 and PARP1 in Triple-Negative Breast Cancer
Cancer cells often lose expression of the p53 protein or express mutant forms of p53. Some of these mutant p53 proteins, called gain-of-function mutant p53, have gained oncogenic functions. Previously, our group observed mutant p53 R273H interacts with replicating DNA and upregulates the chromatin …
-
The identification and functional analysis of mutant p53-G9a oncogenic axis in anaplastic Wilms’ tumour
… by a high frequency of missense mutations in TP53. Despite these potential gain-of-function (GOF) mutations having been reported in the early 1990’s, the biological effects of GOF mutant p53 (mutp53) protein in anaplastic Wilms’ tumour has never been examined. <br/>In this study, we demonstrate …
Page 1 of 8